Switch theme
Sign up to access all valuation multiples
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
2015
131
LTM Revenue $9.6M
LTM EBITDA -$312M
$841M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
IDEAYA Biosciences has a last 12-month revenue of $9.6M and a last 12-month EBITDA of -$312M.
In the most recent fiscal year, IDEAYA Biosciences achieved revenue of $7.0M and an EBITDA of -$323M.
IDEAYA Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IDEAYA Biosciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $23.4M | $7.0M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$130M | -$323M | XXX | XXX | XXX |
| EBITDA Margin | -558% | -4616% | XXX | XXX | XXX |
| Net Profit | -$58.7M | -$113M | XXX | XXX | XXX |
| Net Margin | -251% | -1614% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, IDEAYA Biosciences's stock price is $17.
IDEAYA Biosciences has current market cap of $1.5B, and EV of $841M.
See IDEAYA Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $841M | $1.5B | XXX | XXX | XXX | XXX | $-3.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, IDEAYA Biosciences has market cap of $1.5B and EV of $841M.
IDEAYA Biosciences's trades at 87.5x LTM EV/Revenue multiple, and -2.7x LTM EBITDA.
Analysts estimate IDEAYA Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for IDEAYA Biosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $841M | XXX | XXX | XXX |
| EV/Revenue | 120.1x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | XXX | XXX |
| P/E | -5.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpIDEAYA Biosciences's NTM/LTM revenue growth is 195%
IDEAYA Biosciences's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $2.5M for the same period.
Over next 12 months, IDEAYA Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate IDEAYA Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for IDEAYA Biosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -70% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -4616% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 148% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -4422% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 561% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4210% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 4771% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IDEAYA Biosciences acquired XXX companies to date.
Last acquisition by IDEAYA Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . IDEAYA Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was IDEAYA Biosciences founded? | IDEAYA Biosciences was founded in 2015. |
| Where is IDEAYA Biosciences headquartered? | IDEAYA Biosciences is headquartered in United States of America. |
| How many employees does IDEAYA Biosciences have? | As of today, IDEAYA Biosciences has 131 employees. |
| Who is the CEO of IDEAYA Biosciences? | IDEAYA Biosciences's CEO is Mr. Yujiro S. Hata. |
| Is IDEAYA Biosciences publicy listed? | Yes, IDEAYA Biosciences is a public company listed on NAS. |
| What is the stock symbol of IDEAYA Biosciences? | IDEAYA Biosciences trades under IDYA ticker. |
| When did IDEAYA Biosciences go public? | IDEAYA Biosciences went public in 2019. |
| Who are competitors of IDEAYA Biosciences? | Similar companies to IDEAYA Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of IDEAYA Biosciences? | IDEAYA Biosciences's current market cap is $1.5B |
| What is the current revenue of IDEAYA Biosciences? | IDEAYA Biosciences's last 12-month revenue is $9.6M. |
| What is the current EBITDA of IDEAYA Biosciences? | IDEAYA Biosciences's last 12-month EBITDA is -$312M. |
| What is the current EV/Revenue multiple of IDEAYA Biosciences? | Current revenue multiple of IDEAYA Biosciences is 87.5x. |
| What is the current EV/EBITDA multiple of IDEAYA Biosciences? | Current EBITDA multiple of IDEAYA Biosciences is -2.7x. |
| What is the current revenue growth of IDEAYA Biosciences? | IDEAYA Biosciences revenue growth between 2023 and 2024 was -70%. |
| Is IDEAYA Biosciences profitable? | Yes, IDEAYA Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
